Proliferative verrucous leukoplakia and its tumor markers: systematic review and meta-analysis

Mirjami Rintala DDS\textsuperscript{1}, Tero Vahlberg MSc\textsuperscript{2}, Tuula Salo DDS, PhD\textsuperscript{3-6}, Jaana Rautava DDS, PHD\textsuperscript{1,7}

\textsuperscript{1}Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Turku, Finland
\textsuperscript{2}Biostatistics, Department of Clinical Medicine, University of Turku and Turku University Hospital, Turku, Finland
\textsuperscript{3}Helsinki University Central Hospital, Helsinki, Finland.
\textsuperscript{4}Department of Oral Pathology, Institute of Dentistry, University of Helsinki, Helsinki, Finland
\textsuperscript{5}Finland Cancer and Translational Medicine Research Unit, University of Oulu, Oulu, Finland.
\textsuperscript{6}Medical Research Center Oulu, Oulu, Finland.
\textsuperscript{7}Department of Pathology, Turku University Hospital, Turku, Finland

Corresponding author and author for reprint requests:
Mirjami Rintala, Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine, University of Turku, Lemminkäisenkatu 2, FIN-20520 Turku, Finland
Telephone number: +358505991986
E-mail: rintala.mirjami@gmail.com

Running title: Tumor markers in proliferative verrucous leukoplakia

Keywords: Biomarker, ploidy, proliferative verrucous leukoplakia, squamous cell carcinoma, oral cavity
ABSTRACT

**Background.** The aim was to update information on oral proliferative verrucous leukoplakia (PVL), a disease of verrucous-like lesions with high risk of malignancy, and its biomarkers.

**Methods.** A systematic search of literature on PVL and its biomarkers showed 22 biomarkers that were investigated in 19 papers. A meta-analysis was possible for human papillomavirus (HPV), aneuploidy, Ki-67 and p53.

**Results.** Aneuploidy was found consistently ($I^2=0\%$, $p=0.61$) in 92% (95% CI 80-99%) of the PVL cases. P53 positivity prevalence was 27% (95% CI 15-40%) in two available studies ($I^2=0\%$, $p=0.64$). With HPV and Ki-67 the most outlying studies needed to be removed and after that the pooled HPV positivity prevalence ($I^2=24\%$, $p=0.27$) was 5% (95% CI 0-14%) and for Ki-67 ($I^2=9\%$, $p=0.33$) 14% (95% CI 6-26%).

**Conclusions.** With the evidence of the current literature, aneuploidy could value as a biomarker of PVL but should be further validated.
INTRODUCTION

In 1985, Hansen et al. first described proliferative verrucous leukoplakia (PVL) as a long-term progressive condition, which develops initially as a white plaque of hyperkeratosis that eventually becomes a multifocal disease.\(^1\) Since then several improvements of the classification have been suggested.\(^2,3\) The temporal clinical evolution of PVL has been proposed to follow four stages according to Gillenwater et al. (2013): 1) one or more early focal presentations on the oral mucosa; 2) enlargement and spread over time (geographic expansion); 3) development of a verrucous appearance; 4) development of oral SCC.\(^4\)

PVL often resists attempts of therapy and has a high rate of recurrence and malignancy to verrucous carcinoma (VC) and to invasive squamous cell carcinoma (SCC).\(^4-8\) Because of the aggressiveness of PVL toward malignancy, early detection and careful follow-up of the lesion is essential. However, early detection is not straightforward. Even though PVL is a distinct clinical diagnosis, it is at the same time an elusive lesion. It is in fact impossible to distinguish the early presentation of PVL from other leukoplakias or lichenoid reactions either grossly or microscopically.\(^9\) Therefore, the diagnosis of PVL can only be made through the careful observation of the temporal clinicopathologic evolution of the lesion.\(^4,10\)

An additional difficulty with the diagnosis of PVL is that it is a both a clinical diagnosis that encompasses a spectrum of different clinical and histopathological stages and also a histopathological diagnosis. For the clinical diagnosis of PVL, it is not necessary to have the histopathological diagnosis of PVL. Instead, the histology of PVL is varied and the spectrum of clinical PVL encompasses stages beginning from
benign hyperplasia to histological diagnosis of PVL followed by VC.\textsuperscript{1,2,4} These verrucous lesions are in themselves diagnostically challenging and the terminology is confusing. For example, PVL and VC can be impossible to distinguish from each other clinically and it is also challenging histologically.\textsuperscript{11}

A tumor marker is a biomarker that changes in tumor growth (benign or malignant) compared to the normal counterpart. There are many tumor markers and each indicates a particular disease process. Tumor markers are used in oncology to help detect the presence of cancer, monitoring the cancer with/after treatment and predicting the behavior of cancer/patient survival. Tumor markers can be used with potentially malignant lesions, such as PVL, for example predicting which lesion/s are more likely to proceed to cancer. In PVL, different tumor markers have been evaluated. However, there is no systematic review or meta-analysis available on tumor markers in PVL and neither is any marker in clinical use for helping PVL diagnostics or treatment/follow-up.

The present study had two aims. First, to review all published cases on tumor markers in PVL and meta-analyze all possible tumor markers.
MATERIALS AND METHODS

The search

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines\textsuperscript{12} were used in this review and the literature search flow is shown in Figure 1. With the assistance of an information specialist, a comprehensive search for PVL and its markers was conducted. The entry terms: (((proliferative AND verrucous) OR multifocal) AND (leukoplakia OR leucoplakia)) AND (marker* OR "tumor marker*" OR "tumour marker*" OR biomarker* OR histol* OR histop* OR immunohisto* OR virus OR cytokine* OR “gene muta*”) were used to search PubMed, Scopus, and Web of Science. In PubMed MeSH terms were also used: Leukoplakia, Oral/ Biomarkers, Tumor/ Immunohistochemistry/ Viruses/ Cytokines.

Inclusion and exclusion criteria

The papers on PVL published from 1985 (the year Hansen et al defined PVL\textsuperscript{1}) until the end of 2017 were included. The inclusion criterion of the papers was that at least one marker was studied with PVL (including retrospective case-control studies and case series). The diagnosis of PVL was done by the authors of the papers, diagnosed according to the criteria they used. Any biomarker analyzed from a tissue/cell sample was included. Exclusion criteria were the following: studies not found through PubMed, Scopus or Web of Science, studies in a language other than English, case reports, and studies not peer reviewed.

The study by Femiano et al. (2001)\textsuperscript{13} reporting 50 HPV-associated PVL lesions was excluded from the meta-analysis in this study because HPV positivity was an
inclusion criterion for the PVL-lesions in question. Therefore, it is not comparable with the other studies on HPV-infection prevalence. In addition, Gopalakrishnan’s et al. (1997) study had to be excluded from the meta-analysis, because the study did not present the prevalence of p53 positivity and therefore was not comparable with the other studies.

**Data extraction and analysis**

The titles and abstracts were first screened by two independent investigators (MR, JR) and then potential titles/abstracts were chosen for a full-text evaluation. Differences of opinion were resolved through discussion. Information extracted from the studies was collected in a Microsoft Excel data collection sheet. General information included lead author, institution/country, and year of publication. Information on patients included number of patients, age, and sex. Information on markers included type of marker, method of study, and conclusion.

**Meta-analysis**

Meta-analysis was conducted using MetaXL (Version 5.3, EpiGear International Pty Ltd). The pooled prevalences with 95% confidence intervals (CI) were calculated with a random effects model. Heterogeneity of the prevalences was examined by using the heterogeneity index $I^2$. If substantial heterogeneity with $I^2>50\%$ was shown, sensitivity analyses were conducted, to assess the possible sources of heterogeneity across the studies. P-values less than 0.05 were considered as statistically significant.
RESULTS

Systematic review

Altogether, in the included 19 articles 22 different markers had been studied in the literature by 16 research groups. The markers were DNA ploidy, human papillomavirus (HPV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), human polyomavirus (HPyV), Ki-67, p53, Mcm2, Mcm5, geminin, p16, p16INK4a, p14ARF, CD34, Bcl-2, COX-2, angiotensinogen (AGT), dipeptidyl peptidase 1 (DPP1), IL-6, transforming growth factor alpha (TGF-alfa), mAb 17.13, and mAb 63.12. Only DNA ploidy, HPV, Ki-67, and p53 had been studied with more than two study groups and were chosen for meta-analysis. Individual studies are shown in Table 1.

Fourteen studies included controls and compared results with either normal oral mucosa, conventional oral leukoplakia, reactive lesions or malignant tumors.^{14-16,18-20,22-24,27-31} Ten studies only analyzed biomarker expression (whether the biomarkers were present or not/strength of staining).^{13,14,18-21,23,26,30,31} Four studies analyzed how biomarker expression was association with clinical and/or histological data.^{22,24,28,29} Three studies correlated the biomarkers expression with progression and/or malignant transformation.^{15,16,25} Two studies included etiology and how the biomarker could aid in early detection of PVL.^{17,27}

Meta-analysis

DNA ploidy
The three available studies\textsuperscript{15-17} included in the meta-analysis were homogenic ($I^2=0\%$, $p=0.61$) and the pooled aneuploidy (abnormal DNA content) prevalence was 92\% (95\% CI 80-99\%) (figure 1). Kahn et al. (1994)\textsuperscript{17} used flow cytometry and cell populations were defined as aneuploid when the DNA index was greater than 1.00. Klanrit et al. (2006)\textsuperscript{16} used a Fairfield image-based ploidy analyzer and a lesion was defined as aneuploid if non-euploid peaks were present or if the number of nuclei with DNA content greater than 5c exceeded 1\%. Gouvea et al. (2013)\textsuperscript{15} used image cytometry and a case was defined as aneuploid when the DNA index exceeded 1.10. Controls in these studies varied and were not comparable between studies.

\textit{HPV}

Six studies\textsuperscript{14,18,21-24} reporting on HPV DNA prevalence in PVL showed high heterogeneity ($I^2=85\%$, $p<0.001$) with the pooled HPV positivity prevalence being 16\% (95\% CI 0-42\%) (figure 2). The study by Palefsky et al. (1995)\textsuperscript{24} gave the impression that HPV may play an important role since eight out of nine lesions of PVL were HPV positive while the rest of the five studies have not been able to replicate this impression. When this outlying study was excluded to decrease the heterogeneity ($I^2=68\%$, $p=0.014$), the pooled HPV positivity prevalence was 8\% (95\% CI 0-22\%). When Campisi’s et al. (2004)\textsuperscript{22} study was also excluded the heterogeneity was no longer an issue ($I^2=24\%$, $p=0.27$) and the pooled prevalence was 5\% (95\% CI 0-14\%). Controls in these studies varied and were not comparable between studies.

\textit{Ki-67}

Four studies\textsuperscript{15,23,25,26} reported on proliferation marker Ki-67 in PVL. On sample level, measurements of the labelling index (LI) over 25\%, was chosen to show Ki-67
positivity, which includes moderate and strong expression of Ki-67. The studies showed heterogeneity ($I^2=86\%$, $p<0.001$) and the pooled Ki-67 positivity prevalence was $20\%$ (95% CI 2-47%). Gouvea et al. (2013)\textsuperscript{15} showed a higher prevalence than the other studies and after excluding this study heterogeneity was not significant ($I^2=9\%$, $p=0.33$) and the pooled Ki-67 positivity prevalence was $14\%$ (95% CI 6-26%).

$p53$
Tumor suppressor marker p53 was studied in three articles\textsuperscript{14,23,25}. Gopalakrishnan’s et al. (1997)\textsuperscript{14} study had to be excluded, because the study did not present the prevalence of p53 positivity and therefore was not comparable with the other studies. On sample level, measurements of the labelling index (LI) over 25%, was chosen to show p53 positivity, which includes moderate and strong expression of p53. The two remaining studies showed with 49 samples the pooled p53 positivity prevalence ($I^2=0\%$, $p=0.64$) to be $27\%$ (95% CI 15-40%).
CONCLUSIONS

This systematic review was able to find 22 different markers evaluated in PVL. Meta-analysis was conducted for four markers DNA ploidy, HPV, Ki-67, and p53, which were studied in more than two study groups as well as in more than one country. HPV seems to be involved only in a minority of PVL lesions, especially when the most outlying studies were excluded (the pooled prevalence 5%, 95% CI 0-14%). The pooled Ki-67 positivity prevalence was also small (14%, 95% CI 6%-26%). In addition, p53 positivity was found in only 27% (95% CI 15-40%) of the PVL samples. On the other hand, DNA ploidy was found in almost all PVL lesions (the pooled positivity prevalence 92%, 95% CI 80-99%). The studies showed good concordance of the results with ploidy and p53 when analyzing all the available studies, whereas when analyzing HPV and Ki-67, the most outlying studies had to be excluded to gain statistical homogeneity.

DNA ploidy is a measurement of DNA content. Abnormal DNA content or aneuploidy is a marker of chromosomal instability that can be due to genetic and epigenetic alterations in carcinogenesis. With PVL, aneuploidy has been suggested as a marker of increased risk of malignant progression with or without epithelial abnormality.\textsuperscript{15} According to this meta-analysis, DNA ploidy seems to be a potential marker for PVL. Already in 1994, Kahn et al.\textsuperscript{17} found aneuploidy in all four of the reported PVL patients, either at first biopsy or during follow-up. In 2007, Klanrit et al.\textsuperscript{16} found aneuploidy in four out of six patients before malignant transformation and suspicion of aneuploidy in a fifth patient. The site of transformation was predicted in three out of six patients by both ploidy analysis and histopathology. The largest and
also the most recent study on DNA ploidy is by Gouvea et al. (2013)\textsuperscript{15} who studied 21 PVL patients. They found that 19 PVL patients out of 20 showed aneuploidy. The aggressiveness of PVL could not be correlated with the different grades of aneuploidy. However, malignant development was predicted by aneuploidy in five out of nine SCC cases.\textsuperscript{15}

A controversy over the role of HPV in PVL has existed. Femiano et al. (2001)\textsuperscript{13} found a large group of 50 HPV-associated PVL-lesions and Palefsky et al. (1995)\textsuperscript{24} found a high percentage of HPV in PVL samples. However, three studies\textsuperscript{18,21,23} have found no evidence of HPV in PVL and two studies\textsuperscript{14,22} have not found a significantly increased risk of HPV infection compared to controls. This includes the largest study by Campisi et al. (2004)\textsuperscript{22}, with 58 patients. There is no gold standard how to detect HPV, which genotypes (one or several, high-risk/low-risk) and whether the infection is passive or active (RNA). Technical differences most likely account for these differences. Contamination is also always a risk with HPV.

In addition to DNA ploidy, HPV, Ki-67, and p53, the biomarker Mcm2 and Epstein-Barr virus (EBV) were studied in more than one study. Fettig et al. (2000)\textsuperscript{23} found that Ki-67 and p53 are overexpressed in ten PVL patients compared to controls (normal mucosa and oral wart). Gopalakrishnan et al. (1997)\textsuperscript{14} found p53 expression but no p53 mutations in ten PVL patients. P53 in PVL was overexpressed compared to normal mucosa and the staining pattern was different from that in SCC. There was no evidence for the role of p53 gene mutations in the progression from PVL to SCC.\textsuperscript{14} According to Gouvea et al. (2013 and 2010)\textsuperscript{15,25} the proliferation markers Mcm2 and Mcm5 could be useful markers for PVL. Gouvea et al. (2010)\textsuperscript{25} studied 12 PVL patients and found higher positivity for Ki-67, p53, Mcm2, and Mcm5 in PVL that had progressed to SCC than in PVL that had not progressed to SCC. Ki-67 and p53
were weakly or moderately or not at all positive for PVL that had not progressed to SCC but high immunoexpression of Mcm2 and Mcm5 was found in some PVL cases that presented as mild or moderate dysplasia. Gouvea et al. (2010)25 hypothesize that high immunoexpression of Mcm2 and Mcm5 in mild and moderate dysplasia could therefore help predict the malignant transformation of PVL. Gouvea et al. (2013)15 found that samples from 21 PVL patients had higher Mcm2 expression than the DNA replication inhibitor geminin and Ki-67 expression. In addition, levels of Mcm2 expression showed a positive correlation with increasingly severe epithelial changes. Therefore, Gouvea et al. (2013)15 hypothesize that Mcm2 expression could be used to predict areas of malignant transformation.

Two studies by Bagan JV et al. (2008)20 and Bagan L et al. (2016a)19 have not been able to show that EBV has a role in the etiology of PVL. In these studies, EBV was found in biopsies of patients with a history of PVL, but the differences between PVL and controls were not statistically significant. In the study published in 200820 EBV was found to be more prevalent in ten PVL patients than in either OSCC or normal mucosa, whereas in the study published in 201619 EBV was found to be most prevalent in OSCC, and more prevalent in nine PVL patients than in normal mucosa. Oncoviruses (herpes- papilloma and polyomaviruses) were not found in ten PVL patients in study by Garcia-Lopez et al. (2014)18.

Sixteen of the biomarkers were studied in only individual studies. For example, IL-6 and TGF-alpha could be potential markers for PVL, since they were overexpressed in PVL lesions compared to normal mucosa, but there is only one study each on the topic.28,30 In addition, the salivary proteins angiotensinogen (AGT) and dipeptidyl peptidase 1 (DPP1) may be potential etiologic biomarkers for PVL, since they were
found to be underexpressed in the saliva of PVL patients compared to healthy controls through salivary proteome examination and statistical analysis.\textsuperscript{27}

IL-6 is a cytokine that participates in the immune response and inflammation and boosts the growth of malignant cells.\textsuperscript{28} Bagan et al. (2016b)\textsuperscript{28} found that 20 PVL patients had significantly higher IL-6 levels than healthy controls, whereas SCC controls had the highest IL-6 level. In PVL patients, the more verrucous the area, the higher the IL-6 level. Bagan et al. (2016b)\textsuperscript{28} claim that these findings show that IL-6 could be a significant tool for monitoring PVL patients.

TGF-alpha is a potent mitogen/growth factor that has an important role in oral carcinogenesis.\textsuperscript{30} Kannan et al. (1996)\textsuperscript{30} studied 10 PVL patients and found increased expression of TGF-alfa in PVL than in normal mucosa (significant) and SCC (not significant). Since then no further studies have been conducted on TGF-alfa and PVL.

One study by Migliorati et al. (1992)\textsuperscript{31} evaluated monoclonal antibodies 17.13 and 63.12 in PVL and found that 16 out of 18 PVL biopsies showed the same pattern of staining as dysplasia and SCC, which differs from normal mucosa. The authors hypothesize that this could aid in diagnostics and help the detection of early epithelial changes associated with malignant transformation.\textsuperscript{31}

Thennevan et al. (2015)\textsuperscript{26} reported varied expression of several biomarkers implicated in carcinogenesis in seven PVL patients, but did not correlate the findings of p16, CD34, bcl-2 and COX-2 with controls. In a study by Kresty et al. (2008)\textsuperscript{29} aberrations in cell cycle regulatory genes p16INK4a and p14ARF were common in 20 PVL patients and the mode and incidence of inactivation events differed from those reported in other potentially malignant lesions (the microsatellite markers used were IFN\textsubscript{x}, D9S1748, and D9S171). According to these few studies it is difficult to say if
more research should be done on these markers and would the research yield useful information.

The reporting of tumor markers varied and was not rigorous. The sample size was often small, ten studies included ten or less PVL patients. Only five studies included twenty or more PVL patient cases. McShane et al. (2005) presented reporting recommendations for tumor marker prognostic studies (REMARK) to encourage transparent and complete reporting to allow the adequate assessment of the quality of the study and the generalizability of the results. Unfortunately, most of the articles on PVL and its biomarkers fell short of these guidelines.

Lack of proper controls was also a challenge. Some studies had no controls at all. Controls used varied from normal oral mucosa to conventional oral leukoplakia and oral squamous cell carcinoma in most cases but also warts and benign hyperplasias were used. Well characterized controls of both normal oral mucosa and squamous cell carcinoma should always be considered for comparative purposes.

The diagnostic criteria for PVL was not uniform in all the studies included and this is the major weakness of this review and meta-analysis. Possibly not all the PVL lesions included would pass the strictest criteria for PVL. Most of the studies address that the diagnosis of PVL can only be made through careful long-term observation and histopathological evaluation was included with each case. However, many of the studies included only one biopsy per patient. At the moment, with the current literature it is not possible to come closer to the truth on biomarker expression with PVL.

One major challenge for systematic analysis was that the presence of overlapping series of patients was not easily discerned based on the information given in the
studies. Three of the patient series were described from Brazil\textsuperscript{15,25,27}. Gouvea et al. (2013)\textsuperscript{15} and Gouvea et al. (2010)\textsuperscript{25} could include partly overlapping series of patients. However, their results on Ki-67 were different suggesting separate materials and both were included in the initial meta-analysis of Ki-67. Because heterogeneity was an issue, Gouvea et al. (2013)\textsuperscript{15} was excluded from further analysis. Five of the patient series were described from Spain.\textsuperscript{18-21,28} Bagan et al. (2008)\textsuperscript{20} and Bagan et al. (2016a)\textsuperscript{19} could possibly have overlapping patients, but since meta-analysis was not done for EBV, this did not pose a problem in this review. Bagan et al. (2007)\textsuperscript{21} and Garcia-Lopez et al. (2014)\textsuperscript{18} both analysed HPV in PVL and possibly have overlapping patients. Bagan et al. (2007)\textsuperscript{21} does not specify where the patients were recruited from. Three of the patient series were described from the University of California, San Francisco.\textsuperscript{23,24,31} However, Fettig et al. (2000)\textsuperscript{23} included patients treated during the years 1995-1999 which is after the publishing of Palefsky et al. (1995)\textsuperscript{24}, so the possibility of overlapping patients is small.

As a conclusion, more well-planned, well-controlled studies on PVL and tumor markers are needed. Multi-centered studies, in order to increase the sample size of this rare condition, with controls would give valuable data. According to this systematic review and meta-analysis, only DNA ploidy so far clearly shows potential as a tumor marker in PVL.
REFERENCES


### Table 1. The nineteen articles included in the systematic review.

<table>
<thead>
<tr>
<th>Marker</th>
<th>1st Author</th>
<th>Year</th>
<th>Country</th>
<th>No. of PVL patients</th>
<th>No. of controls</th>
<th>Gender</th>
<th>Age (mean years)</th>
<th>Method</th>
<th>Context of biomarker analysis</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA ploidy, Mcm2, geminin, Ki-67</td>
<td>Gouvea⁵</td>
<td>2013</td>
<td>Brazil and Guatemala</td>
<td>21</td>
<td>12 NOM samples</td>
<td>PVL F 85.7%</td>
<td>PVL 65.5</td>
<td>IHC, image cytometry</td>
<td>Progression and malignant transformation</td>
<td>19/20 showed aneuploidy, aneuploidy predicted malignancy in 5/9, Mcm2 expression correlated with progression</td>
</tr>
<tr>
<td>DNA ploidy</td>
<td>Klanrit⁶</td>
<td>2007</td>
<td>UK</td>
<td>6</td>
<td>27 fibroepithelial hyperplasia samples</td>
<td>PVL M 1, F 5</td>
<td>PVL 65.8</td>
<td>Fairfield image-based analysis</td>
<td>Malignant transformation</td>
<td>5/6 showed aneuploidy, aneuploidy predicted malignant transformation in 4/6</td>
</tr>
<tr>
<td>DNA ploidy</td>
<td>Kahn⁷</td>
<td>1994</td>
<td>USA, Tennessee</td>
<td>4</td>
<td>0</td>
<td>PVL M 2, F 2</td>
<td>PVL 69</td>
<td>Flow cytometry</td>
<td>Ploidy status, early detection</td>
<td>4/4 showed aneuploidy, 2/4 showed aneuploidy in initial biopsy</td>
</tr>
<tr>
<td>Oncoviruses (EBV, HPV, HSV, HPyV)</td>
<td>García-López⁸</td>
<td>2014</td>
<td>Spain</td>
<td>10</td>
<td>10 OL, 10 OSCC, 10 healthy controls</td>
<td>PVL F 10; OL M 1, F 9; OSCC M 7, F 3; controls M 3, F 7</td>
<td>PVL 70.3, OL 65.5, OSCC 72.1 controls 24.9</td>
<td>PCR</td>
<td>Presence of oncoviruses</td>
<td>No viruses detected</td>
</tr>
<tr>
<td>EBV (salivary)</td>
<td>Bagan L⁹</td>
<td>2016</td>
<td>Spain</td>
<td>9</td>
<td>12 OSCC, 3 homogenous OL, 47 healthy controls</td>
<td>PVL M 1, F 8</td>
<td>PVL 71.6</td>
<td>qPCR</td>
<td>Presence of EBV</td>
<td>Most EBV in OSCC, not statistically significant</td>
</tr>
<tr>
<td></td>
<td>Study</td>
<td>Year</td>
<td>Country</td>
<td>Sample Size</td>
<td>Sex Distribution</td>
<td>Methodology</td>
<td>Findings</td>
<td>Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----</td>
<td>-------</td>
<td>------</td>
<td>---------</td>
<td>-------------</td>
<td>------------------</td>
<td>-------------</td>
<td>----------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBV</td>
<td>Bagan JV</td>
<td>2008</td>
<td>Spain</td>
<td>10</td>
<td>5 OSCC, 5 NOM</td>
<td>PVL F 10; OSCC M 4, F 1; NOM M 3, F 2</td>
<td>Nested PCR</td>
<td>Presence of EBV</td>
<td>Most EBV in PVL</td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td>Bagan JV</td>
<td>2007</td>
<td>Spain</td>
<td>13</td>
<td>0</td>
<td>PVL 13 F</td>
<td>PVL 45-86</td>
<td>qPCR</td>
<td>Presence of HPV</td>
<td>No HPV</td>
</tr>
<tr>
<td>HPV</td>
<td>Campisi²²</td>
<td>2004</td>
<td>Italy</td>
<td>58</td>
<td>90 conventional OL</td>
<td>PVL M 22, F 36; OL M 47, F 43</td>
<td>nested PCR, MY09/11 &amp; GP5+/GP6+</td>
<td>Presence of HPV and association with clinical &amp; histological data</td>
<td>No difference between groups</td>
<td></td>
</tr>
<tr>
<td>HPV</td>
<td>Femiano¹⁴</td>
<td>2001</td>
<td>Italy</td>
<td>50</td>
<td>0</td>
<td>PVL M 20, F 30</td>
<td>PVL 50,92</td>
<td>PCR</td>
<td>Presence of HPV</td>
<td>HPV in all 50 PVL lesions, inclusion criteria in study</td>
</tr>
<tr>
<td>HPV, p53, Ki-67</td>
<td>Fettig²³</td>
<td>2000</td>
<td>USA, California</td>
<td>10</td>
<td>4 NOM, 1 gingival wart</td>
<td>PVL M 6, F 4</td>
<td>PVL 65</td>
<td>IHC, PCR</td>
<td>Presence of HPV, Ki-67 and p53 expression</td>
<td>No HPV, Ki-67 and p53 overexpressed</td>
</tr>
<tr>
<td>HPV, p53</td>
<td>Gopalakrishnan¹⁴</td>
<td>1997</td>
<td>USA, Ohio</td>
<td>10</td>
<td>10 SCC, 10 NOM</td>
<td>n.a.</td>
<td>n.a.</td>
<td>IHC, PCR</td>
<td>Presence of HPV, p53 expression and p53 gene mutation</td>
<td>No difference between groups</td>
</tr>
<tr>
<td>HPV</td>
<td>Palefsky²⁴</td>
<td>1995</td>
<td>USA, California</td>
<td>7</td>
<td>26 OSCC, 13 dysplasias, 8 focal keratosis, 13 fibrous hyperplasias, 4 papillomas</td>
<td>PVL M 1, F 6</td>
<td>PVL 70,1</td>
<td>PCR</td>
<td>Presence of HPV and association with clinical data</td>
<td>8/9 HPV positive</td>
</tr>
<tr>
<td>p53, Ki-67, Mcm-2</td>
<td>Gouvea²⁵</td>
<td>2010</td>
<td>Brazil</td>
<td>12</td>
<td>0</td>
<td>PVL F 12</td>
<td>PVL 69.7</td>
<td>IHC</td>
<td>Progression and malignant</td>
<td>High expression of Mcm-2 and Mcm-5 in</td>
</tr>
<tr>
<td>Biomarker</td>
<td>Study</td>
<td>Country</td>
<td>Year</td>
<td>Patients</td>
<td>PVL Gender</td>
<td>OSCC Gender</td>
<td>Normal Gender</td>
<td>Method(s)</td>
<td>Findings</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------------------------</td>
<td>----------</td>
<td>------</td>
<td>----------</td>
<td>------------</td>
<td>-------------</td>
<td>--------------</td>
<td>------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Mcm-5</td>
<td>Thennevan</td>
<td>India</td>
<td>2015</td>
<td>7</td>
<td>M 1, F 6</td>
<td></td>
<td></td>
<td>IHC</td>
<td>Presence of biomarkers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PVL 63.7</td>
<td></td>
<td></td>
<td>Pathway of proliferative-apoptotic imbalance in PVL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ki-67, p16, CD34, Bel-2, COX-2</td>
<td>Thennevan</td>
<td>India</td>
<td>2015</td>
<td>7</td>
<td>M 1, F 6</td>
<td></td>
<td></td>
<td>IHC</td>
<td>Presence of biomarkers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PVL 63.7</td>
<td></td>
<td></td>
<td>Pathway of proliferative-apoptotic imbalance in PVL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary proteins e.g. AGT and DPP1</td>
<td>Flores</td>
<td>Brazil</td>
<td>2016</td>
<td>15</td>
<td>F 15; healthy controls</td>
<td></td>
<td></td>
<td>Mass spectrometry-based proteomics</td>
<td>Etiology Low expression of AGT and DPP1 in PVL compared to controls</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PVL 68.13; healthy controls 65.20</td>
<td></td>
<td></td>
<td>Etiology Low expression of AGT and DPP1 in PVL compared to controls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>Bagan</td>
<td>Spain</td>
<td>2016</td>
<td>20</td>
<td>M 5, F 15; healthy controls</td>
<td></td>
<td></td>
<td>ELISA</td>
<td>IL-6 levels and association with clinical data, e.g. extent of verrucous area.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PVL 68; OSCC 65; healthy controls n.a.</td>
<td></td>
<td></td>
<td>IL-6 levels and association with clinical data, e.g. extent of verrucous area.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p16INK4a and p14ARF</td>
<td>Kresty</td>
<td>USA, Ohio</td>
<td>2008</td>
<td>20</td>
<td>Patient matched normal tissue</td>
<td></td>
<td></td>
<td>PCR</td>
<td>Presence of alterations in genes and association with clinical data</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PVL M 8, F 12</td>
<td></td>
<td></td>
<td>PCR</td>
<td>Presence of alterations in genes and association with clinical data</td>
<td></td>
</tr>
<tr>
<td>TGF-alfa</td>
<td>Kannan</td>
<td>USA, Ohio</td>
<td>1996</td>
<td>10</td>
<td>M 2, F 8; OSCC M 5, F 5; normal M 4, F 6</td>
<td></td>
<td></td>
<td>IHC, cytoplasmic optical density (Roche Image analysis system)</td>
<td>Expression of TGF-alfa Increased immunoreactivity in PVL and OSCC</td>
<td></td>
</tr>
<tr>
<td>mAb 17.13 and 63.12</td>
<td>Migliorati</td>
<td>USA, California</td>
<td>1992</td>
<td>18</td>
<td>123 other normal or diseased</td>
<td></td>
<td></td>
<td>immunoperoxidase technique</td>
<td>Reactivity of mAb 17.13 and 63.12</td>
<td>PVL showed same pattern as dysplasia and OSCC</td>
</tr>
<tr>
<td>human oral mucosa</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* PVL = proliferative verrucous leukoplakia, M = male, F = female, IHC = immunohistochemistry, EBV = Epstein Barr virus, HPV = human papillomavirus, HSV = herpes simplex virus, HPyV = human polyomavirus, NOM = normal oral mucosa, OL = oral leukoplakia, OSCC = oral squamous cell carcinoma, PCR = polymerase chain reaction, qPCR = quantitative polymerase chain reaction, ELISA = enzyme-linked immunosorbent assay, AGT = angiotensinogen, DPP1 = dipeptidyl peptidase 1, mAb = monoclonal antibody, n.a. = data not available